Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced a program to accelerate the clinical development of its NR2F6 therapies. The Company intends to combine modified mRNA technology with Regen's existing siRNA ( small interfering RNA) intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.
mRNA is a single-stranded molecule that carries genetic code from DNA in a cell's nucleus to ribosomes (the cell's protein-making machinery).
Regen has filed an Investigational New Drug Application (IND#16928) for their drug termed tCellVax with the U.S. FDA. tCellVax is intended to utilize siRNA to silence NR2F6 activity in human immune cells thereby activating these immune cells in such a way that they can attack cancer cells. The Company believes that adding new intellectual property utilizing modified mRNA will profoundly simplify the drug development process and thus speed development.
San Diego’s Regen BioPharma ($RGBP) has started a preclinical program aimed at creating the first cord blood-based cancer immunotherapeutic that will use the NR2F6 immunological checkpoint.
In a provisional patent application, the tiny, early-stage biotech said it was seeking to create a generation of cord blood-derived killer cells whose anticancer activity was helped by gene silencing.
The product in development, known as ucVax, will be a “universal donor” cellular immunotherapy--which can be shipped frozen to the site of use and does not involve complex cellular manipulations by the treating institution, as current versions of this type of therapy require.
